Science

Biomethane fuel offers negative carbon footprint

Although the EU Commission wants to abolish the internal combustion engine in individual transport through eMobility, biofuels are far from dead, according to a new study.

Read more
Recycling

Carbios raises €141m to boost enzymatic PET recycling

In an oversubscribed capital increase, Carbios SAS has raised €141m, the largest on Euronext growth since 2015.

Read more
Financing

EG 427 expands Series A closing to €18m

Paris-based gene therapy vector specialist EG 427 SAS has closed a Series A financing at €18m raising additional €5m in the final closing.

Read more
Novel Food

Tasteful plant protein

Conventional meat production contributes to 15% of the global greenhouse gas emissions, high energy consumption and land use change. Belgian Paleo NV produces alternative protein from myoglobins of different species.

Read more
Flash Therapeutics

New President for Flash Therapeutics

Toulouse-based Flash Therapeutics has appointed Jerome Bedier as its new President.

Read more
Financing

Seed money for unique topical hair growth inducer

Mallia Therapeutics GmbH has raised seed money to accelerate preclinical research and start Phase I testing of a baldness cure with unique MOA named soluble CD83.

Read more
Collaboration

Evotec earns US$40m in global licence deal with BMS

German CRO Evotec SE enters licence agreement Bristol Myers Squibb within its neuroscience partnership providing US$40m upfront, milestones and double-digit sales royalities.

 

Read more
Deal

Nanobiotix SA licences NBTXR3 to J&J

Paris-based Nanobiotix SA has signed a potential US$1.8bn oncology deal with Janssen Pharmaceutica NV for the global commercialisation rights of its radioenhancer NBTXR3.

Read more
Financing

Living therapy: Microbial immunotherapy of Exeliom Biosciences gets a boost

Exeliom Biosciences, a French company focused on the microbiome-immunomodulation axis to develop next-generation immunotherapies, has announced the closing of its €24m (US$26m) Series A financing to advance the clinical development of its therapeutic pipeline, including several clinical trials of EXL01, a novel bacterial immunotherapy with applications in cancer and infectious diseases.

Read more